| Ytd | 69.55% | |
| 1y | 311.40% |
| Open | 39.09 | Prev Close | 38.85 | Low | 38.62 | High | 47.36 | Mkt Cap | 2.13B |
| Vol | 508.03K | Avg Vol | 403.02K | EPS | -1.08 | P/E | -43.77 | Forward P/E | -14.60 |
| Beta | 2.29 | Short Ratio | 5.73 | Inst. Own | 103.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 34.38 | 200-d Avg | 27.72 | 1yr Est | 45.00 |
SEPN News
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus E
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted avera
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotec
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus E
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clini
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus E
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, wi
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
Septerna, Inc. (NASDAQ: SEPN - Get Free Report)'s stock price traded down 5.9% during trading on Fri
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collab
